Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre

Nicoletta Ciccarelli, Roberto Cauda, Simona Di Giambenedetto, Alberto Borghetti, Annalisa Mondi, Roberta Gagliardini, Alessandro D'Avino, Federico Pallavicini, Andrea De Luca, Massimiliano Fabbiani, B Piccoli, S Lamonica

Risultato della ricerca: Contributo in rivistaContributo a convegnopeer review

Abstract

According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.
Lingua originaleEnglish
pagine (da-a)19817-19817
Numero di pagine1
RivistaJournal of the International AIDS Society
Volume17
DOI
Stato di pubblicazionePubblicato - 2014
EventoHIV Drug Therapy Glasgow Congress 2014 - Glasgow
Durata: 2 nov 20146 nov 2014

Keywords

  • HIV
  • therapy

Fingerprint Entra nei temi di ricerca di 'Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre'. Insieme formano una fingerprint unica.

Cita questo